REPL — Replimune Group, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1737953 ·
Last close
$15.24
Market Cap
$1.43B
52W High
$15.67
52W Low
$3.93
ADV30
6,281,804
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -72,872,000 | -73,217,000 | 332,388,000 | 209,024,000 | 166,228,000 |
| Dec 2025 | 0 | — | -71,527,000 | -70,930,000 | 333,590,000 | 122,951,000 | 123,051,000 |
| Sep 2025 | 0 | — | -83,914,000 | -83,100,000 | 389,450,000 | 102,298,000 | 126,114,000 |
| Jun 2025 | 0 | — | -90,002,000 | -86,693,000 | 469,507,000 | 97,373,000 | 132,792,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-280,344,000
Investing CF
$310,843,000
Financing CF
$66,294,000
CapEx
$-4,223,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.41
As of
2026-07-05
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,262,519,000
Inventory
—
Receivables
$1,619,000
ST Investments
$59,865,000
EBIT TTM
$-305,632,000
Pretax Income TTM
$-314,491,000
Interest Exp TTM
$8,859,000
Analysts
6
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | -318,315,000 | -313,940,000 | 332,388,000 | 166,228,000 | — | -280,344,000 |
| Mar 2025 | 0 | -259,854,000 | -247,297,000 | 551,328,000 | 135,485,000 | — | -192,250,000 |
| Mar 2024 | 0 | -232,853,000 | -215,794,000 | 487,722,000 | 113,214,000 | — | -185,467,000 |
| Mar 2023 | 0 | -174,166,000 | -174,284,000 | 646,591,000 | 91,299,000 | — | -128,050,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-172,891,000
OpCashFlow TTM
$0
Assets (Latest)
$551,328,000
Forward EPS
$-1.37
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| INBX | Inhibrx Biosciences, Inc. | $1.44B | $98.36 | — |
| SLBT | SL Science Holding Ltd | $1.50B | $2.67 | — |
| GLUE | Monte Rosa Therapeutics, Inc. | $1.36B | $15.95 | — |
| ALVO | Alvotech | $1.36B | $4.01 | — |
| VIR | Vir Biotechnology, Inc. | $1.52B | $8.96 | — |
News headlines (Yahoo Finance, 1h cache)
GeoVax Highlights Gedeptin(R) Tumor-Priming Strategy as Immuno-Oncology Enters New Phase
2026-08-11 13:00 · Yahoo
Why Did ABCL, REPL, ABNB Stocks Hit 52-Week Highs Today?
2026-08-11 02:31 · Yahoo
REPL Stock Hits Near 18-Month High On Pricing Of $150M Offering – But, Retail Sees Share Price ‘Unwinding Over Time’
2026-08-10 16:21 · Yahoo
This Biotech’s Drug Could Treat Hot Flashes. The Stock Is Up 34% on Good News.
2026-08-10 16:20 · Yahoo
Replimune’s First Commercial Drug Arrives—With A 2027 Cash Cliff And 2030 Finish Line
2026-08-08 00:31 · Yahoo
Replimune Wins FDA Skin Cancer Drug Approval on Third Try. Why the Stock Is Tumbling.
2026-08-07 19:33 · Yahoo
Why Did IOVA, REPL, ROKU Stocks Surge To 52-Week Highs Today?
2026-08-07 02:40 · Yahoo
REPL Stock Slumps 11% After-Hours — What’s Driving The Selloff?
2026-08-06 21:37 · Yahoo
Replimune Announces FDA Accelerated Approval of TUDRIQEVTM in Combination with Nivolumab for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen
2026-08-06 20:00 · Yahoo
Walmart downgraded, Palantir upgraded: Wall Street's top analyst calls
2026-08-04 13:37 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.